Literature DB >> 15319859

Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use.

Anthony J Freeman1, Rosemary A Ffrench, Jeffrey J Post, Charles E Harvey, Stuart J Gilmour, Peter A White, George Marinos, Ingrid van Beek, William D Rawlinson, Andrew R Lloyd.   

Abstract

This report describes subjects who were highly likely to have been repeatedly exposed to hepatitis C virus (HCV) through injection drug use and who remained negative for anti-HCV antibody. Production of virus-specific interferon- gamma by peripheral blood mononuclear cells was seen in the majority of subjects (72%) and was associated with higher-risk behavior. For 92% of the subjects, results of recombinant immunoblot assays demonstrated faint bands against nonstructural proteins. The immune responses described are likely to have been primed and maintained by episodes of subclinical infection without classic seroconversion and may indicate a hepatitis C-resistant phenotype. Vaccine strategies to mimic this response may provide protection against persistent HCV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319859     DOI: 10.1086/422605

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.

Authors:  Sayed F Abdelwahab; Zainab Zakaria; Maha Sobhy; Eman Rewisha; Mohamed A Mahmoud; Mahmoud A Amer; Mariarosaria Del Sorbo; Stefania Capone; Alfredo Nicosia; Antonella Folgori; Mohamed Hashem; Samer S El-Kamary
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

4.  Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study.

Authors:  Theo Heller; Jens Martin Werner; Fareed Rahman; Eishiro Mizukoshi; Yuji Sobao; Ann Marie Gordon; Arlene Sheets; Averell H Sherker; Ellen Kessler; Kathleen S Bean; Steven K Herrine; M'lou Stevens; James Schmitt; Barbara Rehermann
Journal:  J Infect Dis       Date:  2013-06-24       Impact factor: 5.226

5.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

6.  Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Authors:  Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

7.  Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children.

Authors:  Mohamed Hashem; Hanaa El-Karaksy; Mohamed T Shata; Maha Sobhy; Heba Helmy; Suzan El-Naghi; Gehan Galal; Zainab Z Ali; Gamal Esmat; Sayed F Abdelwahab; G Thomas Strickland; Samer S El-Kamary
Journal:  J Infect Dis       Date:  2011-01-21       Impact factor: 5.226

8.  Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection.

Authors:  D Hegazy; P Thurairajah; M Metzner; A Houldsworth; S Shaw; E Kaminski; A G Demaine; M E Cramp
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

9.  Trace amounts of sporadically reappearing HCV RNA can cause infection.

Authors:  Naga Suresh Veerapu; Su-Hyung Park; Damien C Tully; Todd M Allen; Barbara Rehermann
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

10.  Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Authors:  M T Shata; A Barrett; N J Shire; S F Abdelwahab; M Sobhy; E Daef; S S El-Kamary; M Hashem; R E Engle; R H Purcell; S U Emerson; G T Strickland; K E Sherman
Journal:  J Immunol Methods       Date:  2007-09-19       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.